Discover 779 paid clinical trials in Buffalo, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 779
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Relapsed/Refractory Small Cell Lung Cancer
Location: Buffalo NY, Cleveland OH, Detroit MI, Durham NC,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07325136
Phase 1, Phase 2, Recruiting
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
for
Sarcoma, Childhood Sarcoma of Soft Tissue
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 12 - 70
Code: NCT07402577
Recruiting
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
for
Metastatic Pancreatic Ductal Adenocarcinoma,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT07214298
Phase 1, Phase 2, Recruiting
Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers
for
Psychiatric Disorder
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 21 - 70+
Code: NCT06977503
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
for
Non-Muscle Invasive Bladder Carcinoma,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT06733363
Phase 2, Recruiting
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
for
Extramedullary Disease in Multiple Myeloma,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT06627751
Phase 2, Recruiting
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
for
Recurrent Acute Myeloid Leukemia,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT06871410
Phase 1, Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
for
Large B-cell Lymphoma, Lymphoma, B-Cell,
Location: Buffalo NY, Hackensack NJ, Cincinnati OH, Norfolk VA,
Sponsor: Lyell Immunopharma, Inc.
Sex: All
Age: 18+
Code: NCT07188558
Phase 3, Recruiting
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
for
Basal Cell Carcinoma
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT07182240
Recruiting
New York Better Breathing Study
for
Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8,
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: All
Age: 18+
Code: NCT06869447
Recruiting
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
for
Diffuse Midline Glioma, H3 K27-Altered,
Location: Buffalo NY, Pittsburgh PA, Ann Arbor MI, Baltimore MD,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 21
Code: NCT04870944
Phase 1, Phase 2, Recruiting
Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy
for
Prostate Carcinoma
Location: Buffalo NY
Sponsor: Roswell Park Cancer Institute
Sex: Male
Age: 18+
Code: NCT07075705
Recruiting
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
for
Relapsed Acute Myeloid Leukemia (AML),
Location: Buffalo NY, Philadelphia PA, New York NY, Columbus OH,
Sponsor: Auron Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06846606
Phase 1, Recruiting
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial